ZRO Biosenta Inc

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products

CALGARY, Alberta, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide.

The patented new material science Tri-Filler® products could set the new standard in antimicrobial materials as a safe and proactive option against biological and ecological threats.

“Tri-Filler® has the potential to make a positive impact to the antimicrobial properties of everyday surfaces,” said Am Gill, President and CEO of Biosenta Inc. “We are thrilled to be working with Voran to bring Tri-Filler® to the world marketplace.”

Chelsey Reschke, President and CEO of Voran Group, commented, “Establishing this MOU is the first milestone in our collaboration with Biosenta and we are delighted to be selected as a commercialization partner. The tremendous versatility of the Tri-Filler® products has the potential to revolutionize manufactured building materials and replace existing GHG-intensive commercial fillers. We are especially pleased to work with an impact-driven company like Biosenta.”

Biosenta’s Tri-Filler® is currently being tested at the University of Calgary with very encouraging results (please refer to News Release dated May 25, 2022). Additional updates will be provided in coming weeks.  

About Biosenta Inc.

Biosenta is a Canadian-based company that develops and manufactures a range of safe and environmentally sound chemical compounds for household and industrial applications.

About Voran: Based in Sherwood Park, Alberta, Voran Group is a leader in the development, commercialization, and distribution of advanced antimicrobial solutions. Voran’s pipeline of new products is driven by the demand of its customers, industry, and communities for safer, future-focused solutions. Voran’s capabilities in obtaining market authorizations under the most rigorous global regulatory requirements is the key differentiator in delivering results for its partners and customers.

Disclaimer

The CSE has in no way passed upon the contents of this news release and further, has neither approved nor disapproved of the contents of this news release. Neither the CSE nor its Regulation Services Provider (as such term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”), including forward-looking statements relating the completion of the Transaction. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. If any such risks actually occur, they could impact the potential for discussion, agreement or completion of the Transaction and/or materially adversely affect the Company’s business, financial condition or results of operations. In that case, the trading price of the Company’s common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

For Further Information please contact:

Am Gill, President and CEO of Biosenta Inc.



or

Chelsey Reschke, President and CEO of Voran Group Ventures Ltd.



EN
12/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biosenta Inc

 PRESS RELEASE

Biosenta Announces Breakthrough Discovery in Anti-Microbial Efficacy o...

Biosenta Announces Breakthrough Discovery in Anti-Microbial Efficacy of Tri-Filler™ in Collaboration with Dr. Ian Lewis and Dr. Maen Husein's Labs TORONTO and CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is thrilled to announce a pivotal discovery led by Dr. Mehdi Mohammadi Ashani, a Postdoctoral Researcher under the mentorship of Dr. Ian Lewis and Dr. Maen Husein at the University of Calgary. Utilizing the advanced capabilities of the Alberta Centre for Advanced Diagnostics (ACAD), this research has revealed that Tri-Filler™,...

 PRESS RELEASE

Biosenta builds on partnership with AMPAK to test and commercialize Tr...

Biosenta builds on partnership with AMPAK to test and commercialize Tri-Filler™ CALGARY, Alberta, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) listed on the CSE (CSE: ZRO) is pleased to announce the next level of partnership with AMPAK Inc. and the University of Calgary. The new Agreement will see Tri-Filler™ being tested in plastics at AMPAK Inc. facilities with an eye to commercialization. Further to the announcement of the partnership on September 24th, 2020, AMPAK Inc. has signed a new agreement with Biosenta and the University of Calgary that will g...

 PRESS RELEASE

Biosenta announces further advances in research and development of Tri...

Biosenta announces further advances in research and development of Tri-Filler™ TORONTO and CALGARY, Alberta, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is pleased to announce further advances in research and development of the Tri-Filler™ particle composed of Ca(OH)2 (calcium hydroxide) core with a CaCO3 (calcium carbonate) encapsulation. Ongoing development of new methods of production of Tri-Filler™ by Dr. Maen Husein of the Department of Chemical Engineering at the University of Calgary and his team have reduced aggregation and resulted in ...

 PRESS RELEASE

Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd.

Biosenta Inc. ceases negotiations with Voran Group Ventures Ltd. CALGARY, Alberta, May 31, 2023 (GLOBE NEWSWIRE) -- Biosenta Inc. ( “Biosenta”) (CSE: ZRO) announces that, further to its news release dated October 12, 2022, it has ceased negotiations with Voran Group Ventures Ltd. in respect of the previously announced Memorandum of Understanding dated October 5, 2022, for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide. About Biosenta Inc. Biosenta is a Canadian-based company that develops and manufactures a range of safe and envi...

 PRESS RELEASE

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to col...

Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to collaborate on the commercialization of Biosenta’s Tri-Filler® Products CALGARY, Alberta, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO) has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. (“Voran”) which will lead the way for the commercialization of Biosenta’s Tri-Filler® antimicrobial products in Canadian markets and worldwide. The patented new material science Tri-Filler® products could set the new standard in antimicrobial ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch